Insmed (NASDAQ:INSM) Share Price Crosses Above 200 Day Moving Average - What's Next?

Insmed logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Insmed shares surged 20.6% and crossed above their 200-day moving average of $122.79, reaching an intraday high of $149.07 before last trading at $144.46.
  • Takeover speculation—after reports that Sanofi may consider buying the company—has fueled expectations of a premium; unusually active trading and options activity reflect heightened interest but do not confirm a deal.
  • Analysts’ consensus rating is Moderate Buy, with an average price target of $196.52. In its latest quarter, Insmed beat revenue expectations and grew revenue 268.4% year over year, but its loss per share was wider than analysts expected.
  • Five stocks to consider instead of Insmed.

Insmed, Inc. (NASDAQ:INSM - Get Free Report) passed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $122.79 and traded as high as $149.07. Insmed shares last traded at $144.46, with a volume of 14,399,052 shares traded.

Key Stories Impacting Insmed

Investors following INSM have been watching these stories:

  • Positive Sentiment: Reports that Sanofi is considering buying Insmed prompted investors to price in the possibility of a takeover premium. Bloomberg Law article
  • Positive Sentiment: An analyst cited in coverage suggested Insmed could be worth $170–$210 per share in a takeover, adding to investor expectations for a premium. Seeking Alpha article
  • Neutral Sentiment: Trading activity was unusually elevated, including increased call-option purchases, while a brief LULD pause reflected sharp volatility. These signals show heightened interest but do not confirm a transaction. Proactive Investors article

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Wells Fargo & Company raised their target price on shares of Insmed from $161.00 to $169.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. Truist Financial reaffirmed a "buy" rating and issued a $195.00 price target (up from $185.00) on shares of Insmed in a report on Monday, August 10th. JPMorgan Chase & Co. cut their price objective on Insmed from $179.00 to $175.00 and set an "overweight" rating for the company in a research report on Monday, August 10th. Raymond James Financial set a $173.00 price objective on Insmed in a research note on Tuesday, October 20th. Finally, Mizuho set a $154.00 target price on Insmed in a report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $196.52.

View Our Latest Stock Analysis on INSM

Insmed Trading Up 20.6%

The company's 50-day moving average is $110.85 and its 200 day moving average is $122.79. The company has a current ratio of 2.86, a quick ratio of 2.59 and a debt-to-equity ratio of 0.77. The firm has a market cap of $31.69 billion, a PE ratio of -51.23 and a beta of 0.83.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.08). The business had revenue of $524.43 million during the quarter, compared to analysts' expectations of $500.36 million. Insmed had a negative net margin of 39.85% and a negative return on equity of 96.38%. Insmed's revenue for the quarter was up 268.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.75) EPS. As a group, sell-side analysts predict that Insmed, Inc. will post -1.86 EPS for the current year.

Insiders Place Their Bets

In other news, Director David Brennan sold 25,000 shares of the company's stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total value of $3,100,000.00. Following the transaction, the director owned 39,238 shares in the company, valued at $4,865,512. This represents a 38.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in INSM. Pictet Asset Management Holding SA boosted its stake in shares of Insmed by 44.0% during the 3rd quarter. Pictet Asset Management Holding SA now owns 1,757,541 shares of the biopharmaceutical company's stock valued at $200,845,000 after buying an additional 537,188 shares during the period. Bellevue Group AG increased its stake in shares of Insmed by 8.2% in the third quarter. Bellevue Group AG now owns 1,508,034 shares of the biopharmaceutical company's stock worth $172,127,000 after acquiring an additional 114,616 shares during the last quarter. Sei Investments Co. raised its holdings in shares of Insmed by 56.8% during the first quarter. Sei Investments Co. now owns 1,395,794 shares of the biopharmaceutical company's stock worth $228,239,000 after acquiring an additional 505,624 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Insmed during the second quarter worth $139,966,000. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Insmed by 480.4% during the third quarter. Assenagon Asset Management S.A. now owns 1,266,788 shares of the biopharmaceutical company's stock worth $144,591,000 after acquiring an additional 1,048,518 shares in the last quarter.

Insmed Company Profile

(Get Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Insmed Right Now?

Before you consider Insmed, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.

While Insmed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines